Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(+)-curcuphenol is a natural sesquiterpene phenol primarily isolated from marine sponges, such as *Myrmekioderma* sp. and *Didiscus aceratus*. It is recognized for its potent biological activities, including significant cytotoxicity and antiviral properties. In oncology research, (+)-curcuphenol has demonstrated the ability to inhibit the growth of various cancer cell lines, including A549 (lung cancer) and HeLa (cervical cancer), by inducing apoptosis. This pro-apoptotic effect has been characterized through annexin V and propidium iodide (PI) staining and supported by molecular docking studies. Furthermore, the compound exhibits antiviral activity against Dengue virus type 2 (DENV-2). While it serves as a promising lead compound for drug discovery, it is currently in the early stages of preclinical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (+)-curcuphenol.